Megestrol acetate for cachexia–anorexia syndrome. A systematic review

In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for anorexia and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz‐García, Vicente, López‐Briz, Eduardo, Carbonell‐Sanchis, Rafael, Bort‐Martí, Sylvia, Gonzálvez‐Perales, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989756/
https://www.ncbi.nlm.nih.gov/pubmed/29542279
http://dx.doi.org/10.1002/jcsm.12292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989756/
https://www.ncbi.nlm.nih.gov/pubmed/29542279
http://dx.doi.org/10.1002/jcsm.12292

Ejemplares similares